Mark Newman
Direttore Tecnico/Scientifico/R&S presso GEOVAX LABS, INC.
Patrimonio netto: - $ in data 30/04/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Robert McNally | M | 76 | 18 anni | |
| David Dodd | M | 74 | 14 anni | |
| Mark Reynolds | M | 62 | 18 anni | |
| Randal Chase | M | 74 | 9 anni | |
| John Spencer | M | 83 | 18 anni | |
| Dean Kollintzas | M | 50 | 18 anni | |
| Nicole Lemerond | F | 48 | 2 anni | |
| Kelly McKee | M | 74 | 2 anni | |
| John Sharkey | M | 67 | 2 anni | |
| Erica Raiden | F | - | 2 anni | |
| Jayne Morgan | M | 61 | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Steven S. Antebi | M | 80 | 2 anni | |
| Achim Kaufhold | M | 66 |
Pharmexa A/S
 Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | 2 anni |
| Ted Greene | M | 81 |
Epimmune, Inc.
| - |
| Georges Hibon | M | 86 |
Epimmune, Inc.
| - |
| Emile Loria | M | 74 |
Epimmune, Inc.
| 4 anni |
| William T. Comer | M | 85 |
Epimmune, Inc.
| 11 anni |
| Robert J. de Vaere | M | 66 |
Epimmune, Inc.
| 5 anni |
| Michael Grey | M | 71 |
Epimmune, Inc.
| - |
| Peter M. Tsolinas | M | 87 | 2 anni | |
| Peter Nordkild | M | 69 |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | 2 anni |
| Hans Henrik Chrois Christensen | M | 59 |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 19 | 86.36% |
| Danimarca | 3 | 13.64% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Mark Newman
- Contatti personali
